Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Moolec Science S.A. (MLEC)
USD7.12
-0.36 (-4.81%)
KY NASDAQ Healthcare Biotechnology
Address
89 Nexus Way KY1-9009
Grand Cayman, LU, KY
Grand Cayman, LU, KY
CEO
Alejandro Antalich
Website
moolecscience.com
IPO
2021-03-02
CIK 1937737 ISIN KYG6223S1259
Also trades on
NASDAQ Global Market · MLEC (USD)
NASDAQ Global Market · MLECW (USD)
Description
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.12
-0.36 (-4.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
263.5K
Beta
0.27
Float Shares
517.0K
Free Float %
71.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.58% | -3.46% | -33.07% | -43.38% | +25.50% | +97.12% | -93.73% | -98.34% | -99.49% | -99.49% | -99.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
7.12
Low
45.00
+532.0%
Consensus
45.00
+532.0%
Median
45.00
+532.0%
High
45.00
+532.0%
DCF (Unlevered)
3,174.88
+44,491.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-01 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
45.00
+532.0%
|
Quality scores
Altman Z-Score
-1.31
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+5,830.7% ★ Q4'24: +948.3% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-8,979.0% Q4'24: -20.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-24.1% Q4'24: -45.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-27.4% Q4'24: -54.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-58.9% Q4'24: -7.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-83.2% ★ Q4'24: +3.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.58× Q4'24: -14.43× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
5.63M
est: 5.75M (-2.2%)
|
333.61M
est: 6.64M (+4,923.5%)
|
8.63M
8.63M – 8.63M
+30.0% YoY
|
77.33M
77.33M – 77.33M
+795.7% YoY
|
130.77M
130.77M – 130.77M
+69.1% YoY
|
| EBITDA |
-6.16M
est: -238.0K (-2,487.9%)
|
-69.01M
est: -274.8K (-25,017.6%)
|
-357.2K
-357.2K – -357.2K
-30.0% YoY
|
-3.20M
-3.20M – -3.20M
-795.8% YoY
|
-5.41M
-5.41M – -5.41M
-69.1% YoY
|
| EBIT |
-7.19M
est: -314.8K (-2,185.4%)
|
-91.27M
est: -363.4K (-25,017.6%)
|
-472.3K
-472.3K – -472.3K
-30.0% YoY
|
-4.23M
-4.23M – -4.23M
-795.8% YoY
|
-7.15M
-7.15M – -7.15M
-69.1% YoY
|
| Net Income |
-7.31M
est: -12.28M (+40.5%)
|
-111.46M
est: -16.80M (-563.3%)
|
-15.51M
-15.51M – -15.51M
+7.7% YoY
|
2.59M
2.59M – 2.59M
+116.7% YoY
|
12.93M
12.93M – 12.93M
+400.0% YoY
|
| SGA |
7.18M
est: 64.77M (-88.9%)
|
115.25M
est: 74.77M (+54.1%)
|
97.20M
97.20M – 97.20M
+30.0% YoY
|
870.66M
870.66M – 870.66M
+795.7% YoY
|
1.47B
1.47B – 1.47B
+69.1% YoY
|
| EPS |
-2.85
est: -28.50 (+90.0%)
|
-258.75
est: -39.00 (-563.5%)
|
-36.00
-36.00 – -36.00
+7.7% YoY
|
6.00
6.00 – 6.00
+116.7% YoY
|
30.00
30.00 – 30.00
+400.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.29M
OE per share TTM
-2.09
Owner's Yield
-163.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
98.0K
Insider transactions (90d)
7
Beneficial owners (>5%)
6
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bioceres Group PLC | 15.37M | 40.90% | — | 15.37M | — | 15.37M | OO | England and Wales | 2023-01-09 | ↗ |
| 2 | THEO I SCSp | 15.37M | 40.90% | 797.5K | 14.57M | 797.5K | 14.57M | OO | Grand Duchy of Luxembourg | 2023-01-09 | ↗ |
| 3 | BG Farming Technologies Limited | 14.57M | 38.80% | 14.57M | — | 14.57M | — | OO | England and Wales | 2023-01-09 | ↗ |
| 4 | Biotech Company LLC | 2.91M | 7.80% | — | 2.91M | — | 2.91M | OO | Wyoming | 2024-04-17 | ↗ |
| 5 | Gastón Paladini | 2.91M | 7.80% | — | 2.91M | — | 2.91M | OO | Argentina | 2024-04-17 | ↗ |
| 6 | SCHEDULE 13D | 12.00 | 14.00% | 15.17M | — | 15.17M | 11.00 | OO | — | 2023-01-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
+2 vs prev Q
New positions
2
Closed positions
0
Increased
2
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | HRT FINANCIAL LP | 16.6K +16.6K (+100.0%) | 98.0K +98.0K (+100.0%) | 3.85% +3.847 pp | 0.00% +0.000 pp | USD5.92 +0.0% | 1 qtrs NEW |
| 2 | UBS GROUP AG | 2.00 +2.0 (+100.0%) | 12.00 +12.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.50 +7.6% | 1 qtrs NEW |
| 3 | SBI SECURITIES CO., LTD. | 1.00 -26.0 (-96.3%) | 6.00 -1.0 (-14.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.00 +97.3% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-06-30 | Varela Lorenzo Romualdo Mariano | Director | — | — | Ordinary shares | 933 | 7.14 | 6.7K | 0 | D | ↗ |
| 2028-06-30 | Leon Bentancor Oscar Alejandro | Director | — | — | Ordinary shares | 933 | 7.14 | 6.7K | 0 | D | ↗ |
| 2028-06-30 | Falottico Valeria Ines | Officer | — | — | Ordinary shares | 2,222 | 7.14 | 15.9K | 0 | D | ↗ |
| 2028-06-30 | Diaz Dellavalle Paola Alexandra | Officer | — | — | Ordinary shares | 933 | 7.14 | 6.7K | 0 | D | ↗ |
| 2028-06-30 | Core Daniel Joaquin | Director | — | — | Ordinary shares | 933 | 7.14 | 6.7K | 0 | D | ↗ |
| 2028-06-30 | Antalich Raibar Alejandro Carlos | Officer | — | — | Ordinary shares | 3,333 | 7.14 | 23.8K | 0 | D | ↗ |
| 2028-06-30 | Abelleyra Llodra Diego Juan | Director | — | — | Ordinary shares | 933 | 7.14 | 6.7K | 0 | D | ↗ |
| 2026-02-06 | Falottico Valeria Ines | Officer | — | — | Ordinary shares | 2,333 | 28.56 | 66.6K | 0 | D | ↗ |
| 2026-02-06 | Antalich Raibar Alejandro Carlos | Officer | — | — | Ordinary shares | 6,666 | 28.56 | 190.4K | 0 | D | ↗ |
| 2025-06-16 | Montaron Estrada Gloria | Officer | — | — | Ordinary shares | 0 | 0.00 | — | 1,909 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-886.1K
Shares Outstanding
726.1K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alejandro Antalich | Chief Executive Officer | — | male |
| Amit Dhingra | Chief Science Officer | — | male |
| Catalina Jones | Chief of Staff & Sustainability | — | female |
| Henk Hoogenkamp | Co-Founder & Chief Product Officer | — | male |
| Martin Salinas | Co-Founder | — | male |
| Paola Díaz Dellavalle | Chief Technology Officer | — | — |
| Valeria Falottico | Chief Financial Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MLEC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
